Literature DB >> 30525590

Novel Strategies To Activate the Dopamine D1 Receptor: Recent Advances in Orthosteric Agonism and Positive Allosteric Modulation.

Adrian Hall1, Laurent Provins1, Anne Valade1.   

Abstract

The five dopamine receptor subtypes (D1-5) are activated by the endogenous catecholamine dopamine. Sustained research has sought to identify selective ligands for receptor subtypes. In particular, activation of the D1 receptor has attracted attention due to its promising role in neurological diseases. Initial attempts to identify agonists yielded catechol derivatives, mimicking dopamine, with suboptimal DMPK parameters and low selectivity over the D5 subtype. However, more recent efforts to identify ligands capable of activating the D1 receptor have made substantial progress with the identification of non-catechol agonists with suitable properties to progress to clinical studies. In addition, several research groups have identified positive allosteric modulators that offer new potential. Furthermore, structural studies have surprisingly uncovered two potential allosteric binding sites, the most characterized of which appears to be on intracellular loop 2 (ICL2). This review highlights the recent progress in the field, covering both orthosteric and allosteric modes of activation, discusses the elucidation of the allosteric binding sites, and summarizes the clinical development status of various compounds.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30525590     DOI: 10.1021/acs.jmedchem.8b01767

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Synthesis and dopamine receptor pharmacological evaluations on ring C ortho halogenated 1-phenylbenzazepines.

Authors:  Rajan Giri; Hari K Namballa; Ananta Sarker; Ian Alberts; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2020-06-04       Impact factor: 2.823

2.  Structural insights into the human D1 and D2 dopamine receptor signaling complexes.

Authors:  Youwen Zhuang; Peiyu Xu; Chunyou Mao; Lei Wang; Brian Krumm; X Edward Zhou; Sijie Huang; Heng Liu; Xi Cheng; Xi-Ping Huang; Dan-Dan Shen; Tinghai Xu; Yong-Feng Liu; Yue Wang; Jia Guo; Yi Jiang; Hualiang Jiang; Karsten Melcher; Bryan L Roth; Yan Zhang; Cheng Zhang; H Eric Xu
Journal:  Cell       Date:  2021-02-10       Impact factor: 41.582

3.  Identification of C10 nitrogen-containing aporphines with dopamine D1 versus D5 receptor selectivity.

Authors:  Anupam Karki; Reecan Juarez; Hari K Namballa; Ian Alberts; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2020-02-20       Impact factor: 2.823

Review 4.  Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia.

Authors:  Cassandra J Hatzipantelis; Monica Langiu; Teresa H Vandekolk; Tracie L Pierce; Jess Nithianantharajah; Gregory D Stewart; Christopher J Langmead
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-28

5.  Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists.

Authors:  Pingyuan Wang; Daniel E Felsing; Haiying Chen; Sweta R Raval; John A Allen; Jia Zhou
Journal:  ACS Med Chem Lett       Date:  2019-04-05       Impact factor: 4.345

6.  Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates.

Authors:  Olivier Barret; Lei Zhang; David Alagille; Cristian C Constantinescu; Christine Sandiego; Caroline Papin; Jenna M Sullivan; Thomas Morley; Vincent M Carroll; John Seibyl; Jianqing Chen; Chewah Lee; Anabella Villalobos; David Gray; Timothy J McCarthy; Gilles Tamagnan
Journal:  J Nucl Med       Date:  2021-02-12       Impact factor: 10.057

7.  Crystal structure of dopamine D1 receptor in complex with G protein and a non-catechol agonist.

Authors:  Bingfa Sun; Dan Feng; Matthew Ling-Hon Chu; Inbar Fish; Silvia Lovera; Zara A Sands; Sebastian Kelm; Anne Valade; Martyn Wood; Tom Ceska; Tong Sun Kobilka; Florence Lebon; Brian K Kobilka
Journal:  Nat Commun       Date:  2021-06-03       Impact factor: 14.919

8.  Development of pyrimidone D1 dopamine receptor positive allosteric modulators.

Authors:  Kathryn D Luderman; Prashi Jain; R Benjamin Free; Jennie L Conroy; Jeffrey Aubé; David R Sibley; Kevin J Frankowski
Journal:  Bioorg Med Chem Lett       Date:  2020-11-19       Impact factor: 2.823

9.  Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor.

Authors:  Tim J Fyfe; Peter J Scammells; J Robert Lane; Ben Capuano
Journal:  Molecules       Date:  2021-06-22       Impact factor: 4.411

10.  Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator (D1PAM), in Healthy Subjects.

Authors:  Darren Wilbraham; Kevin M Biglan; Kjell A Svensson; Max Tsai; William Kielbasa
Journal:  Clin Pharmacol Drug Dev       Date:  2020-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.